AstraZeneca (LSE:AZN) has reported third-quarter 2026 total Revenue of USD 16,209m, up 7% at constant exchange rates, and reconfirmed its full-year guidance. The FTSE 100 drugmaker also detailed 12 positive Phase III readouts so far this year, a USD 2bn Investment in a biotechnology partner and a restructuring programme.

AstraZeneca Q3 2026 results: what was announced

AstraZeneca published its results for the nine months and third quarter of 2026 on the London Stock Exchange. Third-quarter total revenue was USD 16,209m, up 7% on both a reported basis and at constant exchange rates (CER). Product sales rose 5% to USD 15,066m, while alliance revenue increased 36% to USD 1,107m.

Core Earnings Per Share (EPS) for the quarter came in at USD 2.79, up 17% (19% at CER), and reported EPS was USD 2.02, up 23%. For the first nine months, total revenue reached USD 46,881m, up 8% (7% at CER), with core EPS of USD 8.00, up 14%. The core Operating Margin for the quarter was 36%, while the reported operating margin was 27%.

Oncology leads growth across therapy areas

Oncology remained the largest contributor, generating USD 7,765m in the quarter, up 17% at CER. Respiratory & Immunology grew 11% to USD 2,518m and Rare Disease rose 10% to USD 2,633m. In contrast, BioPharmaceuticals CVRM revenue fell 18% at CER to USD 2,639m. By region, US revenue rose 5% to USD 6,899m, Europe grew 12% to USD 3,706m and Emerging Markets increased 4% to USD 4,196m, including China at USD 1,920m, up 3%. The company cited pricing headwinds linked to loss of exclusivity and China's volume-based procurement.

Guidance, pipeline and strategy context

AstraZeneca reconfirmed its full-year 2026 guidance at constant exchange rates, targeting total revenue growth in the mid-to-high single digits and core EPS growth in the low double digits. Its core tax rate is expected to be 18-22%. Management said the Business remains on track for its 2030 ambition.

The group reported 47 approvals in major regions since its fourth-quarter 2025 results, including first approvals for four new medicines. It also recorded 12 positive Phase III readouts year to date, which it said carry a combined peak-year revenue potential of well over USD 10bn, and described 2027 readouts as having potential above USD 20bn. Positive Phase III results were highlighted for programmes including DESTINY-Lung04, DeLLphi-305 and SAFFRON.

AstraZeneca completed a USD 2bn share investment in a biotechnology partner in October, securing rights to about 12.0% of its outstanding common stock alongside a clinical collaboration involving ivonescimab. A separate drug-discovery Partnership involves a USD 40m upfront payment. The restructuring programme is expected to cost up to USD 2.0bn and deliver USD 1.5bn in annualised pre-tax benefits, with savings mainly reinvested in the pipeline.

Key risks highlighted by the update

The release also disclosed setbacks. SERENA-4 did not meet its primary endpoint, eVOLVE-Lung02 was discontinued for futility, AWAKE was stopped for lack of efficacy and the CARDIO-TTRansform trial for Wainua missed its primary endpoint. The decline in CVRM revenue, pricing pressure from generic competition and China procurement, and the execution of a USD 2.0bn restructuring programme are further areas of uncertainty for UK shares in the pharmaceutical sector.

What investors may watch next

Market participants may monitor whether fourth-quarter trading keeps AstraZeneca within its reconfirmed guidance ranges, the progress of the clinical collaboration and the delivery of planned savings under the restructuring programme. Further regulatory decisions and the 2027 readout schedule, which management has framed as a significant revenue opportunity, are also likely to draw attention.

Outlook

The update combines steady revenue growth, faster core earnings growth and an active pipeline with several trial disappointments, showing how a major FTSE 100 company is balancing near-term growth with long-term investment.